31702 - Nabilone (Answered)

Melanie Onn
To ask the Secretary of State for Health, what assessment he has made of the potential merits of making the drug nabilone available on the NHS for people with multiple sclerosis.

George Freeman

We have made no such assessment. Nabilone is not licensed for use in the treatment of multiple sclerosis.

30807 - Cancer: Drugs (Answered)

Heidi Alexander
To ask the Secretary of State for Health, if his Department will publish a patient-friendly guide to inform responses to the consultation on proposals for a new Cancer Drugs Fund.

George Freeman

NHS England and the National Institute for Health and Care Excellence’s (NICE) consultation on draft proposals on the future of the Cancer Drugs Fund closed on 11 February 2016. The NHS England Board agreed a way forward, on 25 February 2016, which will see the new arrangements for the Fund going live on 1 July 2016.

904101 - Innovation (Answered)

John Woodcock
To ask the Secretary of State for Business, Innovation and Skills, what investment the Government is making in innovation in order to safeguard sovereign capability in materials for the defence and nuclear industries.

George Freeman

Through Innovate UK we are investing £300m to support high potential opportunities in advanced materials and manufacturing. This investment is delivered through the High Value Manufacturing Catapult centres, including the Nuclear Advanced Manufacturing Research Centre and the National Composites Centre.

30609 - Health Services (Answered)

Rosie Cooper
To ask the Secretary of State for Health, what guidelines are issued to providers of NHS services on marketing of NHS services alongside private services.

George Freeman

A code of practice for the promotion of National Health Service-funded services was published in March 2008 and no further guidance has been produced since then. With regard to use of the NHS Trademark (logo) the NHS Identity guidelines:

www.nhsidentity.nhs.uk

30710 - Stem Cells: Research (Answered)

Tulip Siddiq
To ask the Secretary of State for Health, pursuant to the Answer of 3 March 2016 to Question 28970, how much public funding for stem cell research has been allocated through the National Institute for Health Research in each year since 2003-04.

George Freeman

The information requested is not available. Spend on research funded directly by the National Institute for Health Research (NIHR) is categorised by Health Research Classification System (HRCS) health categories. There is no HRCS category for stem cell research.

30601 - Progressive Supranuclear Palsy (Answered)

Mr George Howarth
To ask the Secretary of State for Health, what steps his Department is taking to support research into new treatments to relieve symptoms for people with progressive supranuclear palsy.

George Freeman

30600 - Progressive Supranuclear Palsy (Answered)

Mr George Howarth
To ask the Secretary of State for Health, what steps he is taking to improve access to specialist health facilities for people with progressive supranuclear palsy.

George Freeman

There is no specific treatment for progressive supranuclear palsy and management of the condition is symptomatic with appropriate Multi-Disciplinary Team care and support from social care. Often patients are referred on to a specialist in movement disorders either in a hospital or neuroscience centre.

30495 - Progressive Supranuclear Palsy (Answered)

Mr George Howarth
To ask the Secretary of State for Health, how many people have been diagnosed with progressive supranuclear palsy in each of the last five years; and how many such people were (a) women and (b) men aged (i) under 18, (ii) between 18 and 45, (iii) between 45 and 65 and (iv) over 65.

George Freeman

NHS England does not collect this data centrally. Progressive supranuclear palsy is uncommon and is rare below the age of 60. It can be diagnosed by any neurologist and requires no special tests. The diagnosis is purely clinical.

30238 - Out-patients: Databases (Answered)

Andrew Gwynne
To ask the Secretary of State for Health, what steps he is taking to improve the systems for capturing, coding and integrating data from NHS outpatient clinics.

George Freeman

29900 - Tuberous Sclerosis: Children (Answered)

Greg Mulholland
To ask the Secretary of State for Health, if he will take steps to ensure that access to Everolimus for children with tuberous sclerosis complex-related kidney tumours is included in the NHS England draft commissioning policy on that drug.

George Freeman

Pages